Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress

Rhea-AI Summary

Daxor (Nasdaq: DXR) will debut a new rapid, portable blood volume analyzer at the SCCM 2026 Critical Care Congress (Booth #906) in Chicago, March 22–24. The device aims to deliver rapid, lab-quality Blood Volume Analysis to ICUs and diverse clinical settings.

According to Daxor, peer-reviewed studies including a randomized controlled trial report BVA altered fluid and RBC interventions in 44% of cases and reduced mortality by 66% in surgical ICUs; the company positions the device to help address >5 million annual U.S. adult ICU admissions and >$100 billion in related healthcare spending.

News Market Reaction – DXR

+1.63%

1 alert

+1.63% News Effect

On the day this news was published, DXR gained 1.63%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Intervention change rate: 44% Mortality reduction: 66%

2 metrics

Intervention change rate 44% Cases where BVA altered fluid and RBC interventions in surgical ICUs

Mortality reduction 66% Reduction in mortality in surgical intensive care units using BVA

Market Reality Check

Price: $11.48 Vol: Volume 2,544 is at 0.2x t...

low vol

$11.48 Last Close

Volume Volume 2,544 is at 0.2x the 20-day average of 12,427, indicating muted pre-news trading. low

Technical Shares at $11.30 are trading slightly below the $11.42 200-day moving average and 23.43% below the 52-week high.

Peers on Argus

Sector peers showed mixed moves, with one momentum-screened peer (ZJYL) down 1.1...

1 Down

Sector peers showed mixed moves, with one momentum-screened peer (ZJYL) down 1.19% without news, suggesting DXR’s setup was more stock-specific than part of a broad sector rotation.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Conference participation	Positive	-0.7%	CEO featured in virtual investment conference with presentation and 1x1 meetings.
Mar 03	Corporate update	Positive	-0.9%	Shareholder letter highlighting 510(k) clearance, 45% revenue growth, and capital raise.
Mar 03	Earnings and financing	Positive	-0.9%	Reported 45% revenue growth, higher NAV, FDA clearance, and $9M offering.
Feb 24	Program expansion	Positive	-1.7%	Launch of BVA outpatient diagnostic program with 24-hour turnaround and 98% accuracy.
Feb 10	Reporting transition	Positive	-0.4%	Plan to shift to Exchange Act reporting, aligning with operating diagnostics focus.

Pattern Detected

Recent positive corporate, financial, and strategic updates have been followed by modestly negative next-day price reactions, indicating a pattern of selling or profit-taking on good news.

Recent Company History

Over recent months, Daxor has reported strong 2025 financial growth, including operating revenue up 45% YoY and net assets of $45.89M, alongside FDA 510(k) clearance for its next‑generation portable analyzer. It also completed a $9.0M registered direct offering and expanded BVA programs in Tennessee. Despite these milestones, the last five news events all saw modest negative price reactions, so this announcement of a rapid, portable analyzer debut continues a stream of commercialization-focused progress against a backdrop of cautious trading.

Market Pulse Summary

This announcement highlights Daxor’s plan to showcase a rapid, portable blood volume analyzer at a m...

Analysis

This announcement highlights Daxor’s plan to showcase a rapid, portable blood volume analyzer at a major critical care congress, emphasizing easier implementation of Blood Volume Analysis and reported reductions in mortality by 66%. It follows FDA 510(k) clearance, revenue growth, and new program launches detailed in recent filings and news. Investors may watch for adoption metrics, placement growth, and additional clinical data as key indicators of how this technology translates into broader hospital utilization and financial performance.

Key Terms

blood volume analyzer, blood volume analysis (bva), intensive care unit, randomized controlled trial, +1 more

5 terms

blood volume analyzer medical

"will showcase its new, portable blood volume analyzer at the Society"

A blood volume analyzer is a medical device that measures how much blood is circulating in a patient’s body, often used to guide treatment for conditions like heart failure, dehydration, or during surgery. For investors, it matters because demand, regulatory approval, reimbursement and clinical acceptance determine whether the device will generate steady sales—think of it as a reliable fuel gauge for doctors, where wider adoption can signal predictable revenue and market growth.

blood volume analysis (bva) medical

"results making Blood Volume Analysis (BVA) easier to implement across"

A blood volume analysis (BVA) is a medical test that measures how much blood and plasma are circulating in a person's body, often using a safe tracer to track distribution. For investors, BVA matters because it informs diagnosis, treatment decisions, clinical trial outcomes, and reimbursement for drugs or devices affecting blood loss, fluid balance, or heart and kidney function—think of it as checking a vehicle’s fuel tank to guide repair and performance choices.

intensive care unit medical

"fluid management in the ICU to Reduce Mortality and Hospital Length"

An intensive care unit (ICU) is a hospital ward that provides round‑the‑clock monitoring and life‑support for patients with severe, potentially life‑threatening illness or injury. For investors, ICU capacity, staffing and outcomes are key indicators of a health provider’s operational strain and revenue mix—similar to how a restaurant’s kitchen size and staff determine how many customers it can serve during peak hours and how well it performs financially.

randomized controlled trial medical

"Supported by extensive peer-reviewed studies, including a randomized controlled trial,"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

ventilator days medical

"improve healthcare economics by reducing ventilator days and hospital length"

The number of days a patient is supported by a mechanical ventilator, counting each calendar day the device helps breathe for someone in a hospital. Investors use this metric like a “rental day” for crucial equipment: higher ventilator days can signal greater demand for ventilators and related supplies, greater hospital resource use and costs, and potential shifts in revenue or reimbursement for medical device makers and healthcare providers.

AI-generated analysis. Not financial advice.

Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay

Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24.

The new device delivers rapid, lab-quality results making Blood Volume Analysis (BVA) easier to implement across diverse clinical settings. This streamlined workflow positions Daxor to address the high costs associated with the more than five million annual adult ICU admissions in the U.S., which currently exceed $100 billion in annual healthcare spending.

“Supported by extensive peer-reviewed studies, including a randomized controlled trial, Daxor’s BVA has demonstrated significant impact on patient outcomes—altering fluid and red blood cell interventions in 44% of cases and reducing mortality by 66% in surgical intensive care units,” said Michael Feldschuh, Daxor CEO and President. “This conference offers a strategic platform to highlight our new faster, portable analyzer. By providing a more accessible system, we are helping hospitals reshape patient care and improve healthcare economics by reducing ventilator days and hospital length of stay.”

About Society of Critical Care Medicine

The Society of Critical Care Medicine (SCCM) is the largest nonprofit medical organization dedicated to promoting excellence and consistency in the practice of critical care. With members in more than eighty countries, SCCM is the only organization that represents all professional components of the critical care team. The Society offers a variety of activities that ensure excellence in patient care, education, research, and advocacy.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

When and where will Daxor (DXR) showcase its new blood volume analyzer at SCCM 2026?

Daxor will present the portable analyzer at SCCM 2026 in Chicago, March 22–24. According to Daxor, the company will exhibit at Booth #906 at McCormick Place to demonstrate the device and its rapid Blood Volume Analysis workflow to clinicians.

What clinical benefits does Daxor claim for the new DXR blood volume analyzer?

The device is claimed to deliver rapid, lab-quality blood volume results for ICU use. According to Daxor, peer-reviewed studies show BVA altered interventions in 44% of cases and reduced surgical ICU mortality by 66%, improving fluid and transfusion decisions.

How does Daxor say the new DXR analyzer could affect hospital costs and length of stay?

Daxor says the portable analyzer could help reduce ventilator days and hospital length of stay. According to Daxor, by improving fluid management in ICUs the technology targets high costs tied to over 5 million U.S. adult ICU admissions and over $100 billion annual spending.

What evidence does Daxor cite for the effectiveness of its Blood Volume Analysis (BVA)?

Daxor cites extensive peer-reviewed studies, including a randomized controlled trial supporting BVA use. According to Daxor, these studies report changes in clinical interventions in 44% of cases and a 66% mortality reduction in surgical intensive care units.

Will hospitals be able to implement Daxor's BVA more widely with the new portable DXR analyzer?

Daxor says the portable analyzer streamlines BVA workflow to enable broader clinical adoption across settings. According to Daxor, the faster, more accessible system is designed to make BVA easier to implement outside central labs in ICUs and other care areas.